To validate the suitability of our cohort of patients with pancreatic cancer as well as our general analysis set-up to determine differences in serum concentrations of TNF ligands, we first measured APRIL serum concentrations in a subgroup of patients and healthy controls (patients’ characteristics are given in Table 1). This evidence concerns the gene TNF and familial pancreatic carcinoma.